Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Omega-3 health claim

This article was originally published in The Tan Sheet

Executive Summary

FDA amends, shortens qualified health claim for fatty acids/coronary heart disease. In Feb. 8 letter to Emord & Associates, agency says it will allow use of the claim: "Consumption of omega-3 fatty acids may reduce the risk of coronary heart disease. FDA evaluated the data and determined that, although there is scientific evidence supporting the claim, the evidence is not conclusive." Supplements bearing claim must not recommend intake exceeding 2 g/day EPA and DHA. Pearson plaintiffs had complained original 78-word claim, approved in October 2000, failed to accurately summarize scientific knowledge about fatty acids and was too lengthy (1"The Tan Sheet" Nov. 6, 2000, p. 3)...

You may also be interested in...



Structure/Function, Health Claims Often Indistinguishable, OIG Report Finds

Structure/function claims are often unclear regarding supplements' intended use, according to a March 4 report released by the Department of Health & Human Services' Office of the Inspector General

Omega-3/Heart Disease Qualified Supplement Health Claim Allowed

Dietary supplements bearing a qualified health claim for omega-3 fatty acids and coronary heart disease risk reduction must recommend a maximum daily intake of 2 g EPA and DHA, FDA announced Oct. 31.

Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables

Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS093610

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel